Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Redhill Biopharma Ltd

RDHL ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: N/A

Last Close

$0.39

▼ -6.91%

Market Cap $3.45M · Vol 3.17K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.45M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

24.30

Momentum

Beta

4.95

vs Market

52W High

$1.60

75.76% below

52W Low

$0.39

0.73% above

Volume

3.17K

Avg 40.56K

P/B

1.23

Price-to-book

ROE

N/A

Return on equity

Free Float

N/A

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Redhill Biopharma Ltd (RDHL) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RDHL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-8.36%

-19.21%

-38.52%

-64.42%

YTD

-62.35%

-71.27%

-96.47%

-99.99%

Financials & Valuation

TTM · Annual

Total Revenue	$286.00K
Net Income	$-8,080,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-2,765.38%
Net Profit Margin	-2,825.17%
ROE	N/A
ROA · ROIC	-37.25% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	11.38
P/B	1.23
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	88.88B

Technical Indicators

50-Day SMA	$0.56
200-Day SMA	$0.81
RSI (14)	24.30
Beta	4.95
52-Week High	$1.60
52-Week Low	$0.39

Volume Today	3.17K
Avg Daily Volume (30D)	40.56K
Relative Volume	0.08x
Volatility (10D)	81.79
Volatility (30D)	85.24
Free Float	N/A

Analyst Consensus

N/A

Current Price $0.39

Mean Target N/A

52W Low$0.39 52W High$1.60

Current

Target

$0.39 $1.60

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG003RY92J5

ISINUS7574683014

CountryIsrael

Sub-IndustryBiopharmaceuticals

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals, Inc. +13.33% CSL.AX CSL Limited +1.64% UCB.BR Ucb SA +0.50% 207940.KS SAMSUNG BIOLOGICS CO.,LTD. +8.86% BIIB Biogen Inc. +1.59%

Company Profile

RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.